NOVARTIS PIQRAY® RECEIVES POSITIVE CHMP OPINION TO TREAT HR+/HER2- ADVANCED BREAST CANCER WITH A PIK3CA MUTATION

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of Piqray® (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer with …

NOVARTIS PIQRAY® RECEIVES POSITIVE CHMP OPINION TO TREAT HR+/HER2- ADVANCED BREAST CANCER WITH A PIK3CA MUTATION Read More »